Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis

Jose Garnacho-Montero, Teresa Aldabo-Pallas, Carmen Garnacho-Montero, Aurelio Cayuela, Rocio Jiménez, Sonia Barroso, Carlos Ortiz-Leyba, Jose Garnacho-Montero, Teresa Aldabo-Pallas, Carmen Garnacho-Montero, Aurelio Cayuela, Rocio Jiménez, Sonia Barroso, Carlos Ortiz-Leyba

Abstract

Introduction: Genetic variations may influence clinical outcomes in patients with sepsis. The present study was conducted to evaluate the impact on mortality of three polymorphisms after adjusting for confounding variables, and to assess the factors involved in progression of the inflammatory response in septic patients.

Method: The inception cohort study included all Caucasian adults admitted to the hospital with sepsis. Sepsis severity, microbiological information and clinical variables were recorded. Three polymorphisms were identified in all patients by PCR: the tumour necrosis factor (TNF)-alpha 308 promoter polymorphism; the polymorphism in the first intron of the TNF-beta gene; and the IL-10-1082 promoter polymorphism. Patients included in the study were followed up for 90 days after hospital admission.

Results: A group of 224 patients was enrolled in the present study. We did not find a significant association among any of the three polymorphisms and mortality or worsening inflammatory response. By multivariate logistic regression analysis, only two factors were independently associated with mortality, namely Acute Physiology and Chronic Health Evaluation (APACHE) II score and delayed initiation of adequate antibiotic therapy. In septic shock patients (n = 114), the delay in initiation of adequate antibiotic therapy was the only independent predictor of mortality. Risk factors for impairment in inflammatory response were APACHE II score, positive blood culture and delayed initiation of adequate antibiotic therapy.

Conclusion: This study emphasizes that prompt and adequate antibiotic therapy is the cornerstone of therapy in sepsis. The three polymorphisms evaluated in the present study appear not to influence the outcome of patients admitted to the hospital with sepsis.

Figures

Figure 1
Figure 1
Correlation between delta-SOFA and delayed initiation of adequate antibiotic therapy. SOFA, Sequential Organ Failure Assessment.

References

    1. Angus DC, Linde-Zwirble WT, Lidicker L, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310. doi: 10.1097/00003246-200107000-00002.
    1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, CUB-Rea Network Current epidemiology of septic shock. Am J Respir Crit Care Med. 2003;168:165–172. doi: 10.1164/rccm.2201087.
    1. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742–2751. doi: 10.1097/01.CCM.0000098031.24329.10.
    1. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123:1615–1624. doi: 10.1378/chest.123.5.1615.
    1. Yu DT, Black E, Sands KE, Schwartz JS, Hibberd PL, Graman PS, Lanken PN, Kahn KL, Snydman DR, Parsonnet J, et al. Severe sepsis: variation in resource and therapeutic modality use among academic centers. Crit Care. 2003;7:R24–R34. doi: 10.1186/cc2171.
    1. Wax RS, Angus DC. The molecular genetics of sepsis: Clinical epidemiology considerations. In: Vincent JL, editor. 2000 Yearbook of Intensive Care and Emergency Medicine. Springer: Berlin; 2000. pp. 3–17.
    1. Tabrizi AR, Zehnbauer BA, Freeman BD, Buchman TG. Genetic markers in sepsis. J Am Coll Surg. 2001;192:106–117. doi: 10.1016/S1072-7515(00)00748-1.
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee Definition for sepsis and organ failures and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644–1655.
    1. Van Dissel JT, Van Langevelde P, Westendorp RGJ, Kwappenberg K, Frölich M. Anti-inflamatory cytokine profile and mortality in febrile patients. Lancet. 1998;351:950–953.
    1. Mira JP, Cariou A, Grall P, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA. 1999;281:1919–1926. doi: 10.1001/jama.281.20.1919.
    1. Stuber F, Udalova IA, Book M, Drutskaya LN, Kuprash DV, Turetskaya RL, Schade FU, Nedospasov SA. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of human promoter. J Inflamm. 1996;46(1):42–50.
    1. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polumorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.
    1. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–871. doi: 10.1001/jama.288.7.862.
    1. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–1367. doi: 10.1056/NEJMoa011300.
    1. The Acute Respiratory Distress Network Ventilation with lower tidal volumes as compared with traditional volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301–1308. doi: 10.1056/NEJM200005043421801.
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II, a severity of disease classification system. Crit Care Med. 1985;13:818–829.
    1. Pittet D, Thiévent B, Wenzel RP, Li N, Gurman G, Suter P. Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med. 1993;19:265–272. doi: 10.1007/BF01690546.
    1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–710.
    1. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754–1758. doi: 10.1001/jama.286.14.1754.
    1. Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar A, Garnacho-Montero MC, Moyano-Del-Estad MR. Critical illness polyneuropathy: Risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med. 2001;27:1288–1296. doi: 10.1007/s001340101009.
    1. Hosmer DW, Lemeshow SA. Applied Logistic Regression. New York: John Wiley; 1989.
    1. Houch PM, Bratzler DW, Nsa W, Na A, Barlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637–644. doi: 10.1001/archinte.164.6.637.
    1. Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med. 1998;129:862–869.
    1. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohot study. Intensive Care Med. 2002;28:108–121. doi: 10.1007/s00134-001-1143-z.
    1. Legras A, Malvy D, Quinioux AI, Villers D, Bouachour G, Robert R, Thomas R. Nosocomial infections: prospective survey of incidence in five French intensive care units. Intensive Care Med. 1998;24:1040–1046. doi: 10.1007/s001340050713.
    1. Rangel-Frausto M, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of systemic inflammatory response syndrome (SIRS) JAMA. 1995;273:117–123. doi: 10.1001/jama.273.2.117.
    1. Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia AR, Palazzo M, Werdan K, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Resp Crit Care Med. 2005;171:461–468. doi: 10.1164/rccm.200403-324OC.
    1. Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW, Lui WY, Chiu JH, Lee TY. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med. 2000;28:2733–2736. doi: 10.1097/00003246-200008000-00008.
    1. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med. 1996;24:381–384. doi: 10.1097/00003246-199603000-00004.
    1. Schroeder S, Reck M, Hoeft A, Stuber S. Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis. Crit Care Med. 1999;27:1265–1270. doi: 10.1097/00003246-199907000-00006.
    1. Rauchschwalbe SK, Maseizik T, Mittelkotter U, Schluter B, Patzig C, Thiede A, Reith HB. Effect of the LT-alpha (+250 G/A) polymorphism on markers of inflammation and clinical outcome in critically ill patients. J Trauma. 2004;56:815–822.
    1. Gordon AC, Lagan AL, Aganna E, Cheung L, Peters CJ, McDermott MF, Millo JL, Welsh KI, Holloway P, Hitman GA, et al. TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immunity. 2004;5:631–640. doi: 10.1038/sj.gene.6364136.
    1. Heesen M, Kunz D, Bachmann-Mannenga B, Merk HF, Bloemeke B. Linkage disequilibrium between tumor necrosis factor (TNF)-α-308 G/A promoter and TNF β Ncol polymorphisms: association with TNF-α response of granulocytes to endotoxin stimulation. Crit Care Med. 2003;31:211–214. doi: 10.1097/00003246-200301000-00032.
    1. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Resp Crit Care Med. 2001;163:1599–1604.
    1. Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG, O'Neill SJ. Association of Il-10 polymorphism with severity of illness in community acquired pneumonia. Thorax. 2003;58:154–156. doi: 10.1136/thorax.58.2.154.
    1. Schaff BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Resp Crit Care Med. 2003;168:476–480. doi: 10.1164/rccm.200210-1164OC.
    1. Bayley JP, Ottenhoff THM, Verweij CL. Is there a future for TNF promoter polymnorphism. Genes Immunity. 2004;5:315–329. doi: 10.1038/sj.gene.6364055.
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
    1. Carlet J. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Crit Care Med. 2006;34:525–529. doi: 10.1097/01.CCM.0000198329.85851.8E.
    1. Sutherland AM, Walley KR, Manocha S, Russell JA. The association of interleukin 6 haplotype with mortality in critically ill adults. Arch Intern Med. 2005;165:75–82. doi: 10.1001/archinte.165.1.75.
    1. Colhoun HM, Mckeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865–872. doi: 10.1016/S0140-6736(03)12715-8.
    1. Polderman KH, Girbes ARJ. Drug intervention trials in sepsis: divergent results. Lancet. 2004;363:1721–1723. doi: 10.1016/S0140-6736(04)16259-4.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する